Cargando…

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial

INTRODUCTION: Several studies have described prognostic value of serum neurofilament light chain (sNfL) at the group level in relapsing multiple sclerosis (RMS) patients. Here, we aimed to explore the temporal association between sNfL and development of subclinical disease activity as assessed by ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bar-Or, Amit, Montalban, Xavier, Hu, Xixi, Kropshofer, Harald, Kukkaro, Petra, Coello, Neva, Ludwig, Inga, Willi, Roman, Zalesak, Martin, Ramanathan, Krishnan, Kieseier, Bernd C., Häring, Dieter A., Bagger, Morten, Fox, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837345/ https://www.ncbi.nlm.nih.gov/pubmed/36534274 http://dx.doi.org/10.1007/s40120-022-00427-8

Ejemplares similares

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study
por: Bar-Or, Amit, et al.
Publicado: (2021)

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Long-term prognostic value of longitudinal measurements of blood neurofilament levels
por: Häring, Dieter A., et al.
Publicado: (2020)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
por: Gärtner, Jutta, et al.
Publicado: (2022)

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
por: Yu, Huixin, et al.
Publicado: (2022)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2019)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
por: Delcoigne, Bénédicte, et al.
Publicado: (2020)

Serum neurofilament light chain levels associations with gray matter pathology: a 5‐year longitudinal study
por: Jakimovski, Dejan, et al.
Publicado: (2019)

Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study
por: Tavazzi, Eleonora, et al.
Publicado: (2020)

Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
por: Reinert, Marie-Christine, et al.
Publicado: (2020)

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
por: Hauser, Stephen L, et al.
Publicado: (2022)

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
por: Calabresi, Peter A, et al.
Publicado: (2020)

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
por: Varhaug, Kristin N., et al.
Publicado: (2019)

Associations Between Life-Course Lipid Trajectories and Subclinical Atherosclerosis in Midlife
por: Yan, Yinkun, et al.
Publicado: (2022)

Absence of the Mid-sized Neurofilament Subunit Decreases Axonal Calibers, Levels of Light Neurofilament (NF-L), and Neurofilament Content
por: Elder, Gregory A., et al.
Publicado: (1998)

Differential dynamics of neurofilament-H protein and neurofilament-L protein in neurons
Publicado: (1994)

Neurofilament deficiency in quail caused by nonsense mutation in neurofilament-L gene
Publicado: (1993)

Neurofilament light chain level is a weak risk factor for the development of MS
por: Arrambide, Georgina, et al.
Publicado: (2016)

A motor for neurofilaments
por: Dove, Alan W.
Publicado: (2002)

Antibody decoration of neurofilaments
Publicado: (1981)

Partial purification of neurofilament subunits from bovine brains and studies on neurofilament assembly
Publicado: (1981)

Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments
por: Ackerley, Steven, et al.
Publicado: (2003)

Olfactory function, neurofilament light chain, and cognitive trajectory: A 12‐year follow‐up of the Shanghai Aging Study
por: Xiao, Zhenxu, et al.
Publicado: (2023)

Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2020)

Neurofilament-dependent Radial Growth of Motor Axons and Axonal Organization of Neurofilaments Does Not Require the Neurofilament Heavy Subunit (NF-H) or Its Phosphorylation
por: Rao, Mala V., et al.
Publicado: (1998)

Neurofilament subunit NF-H modulates axonal diameter by selectively slowing neurofilament transport
Publicado: (1996)

Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode
por: Plavina, Tatiana, et al.
Publicado: (2020)

Trajectories of Symptom Change in School-Based Prevention Programs for Adolescent Girls with Subclinical Depression
por: Bossenbroek, Rineke, et al.
Publicado: (2022)

Subclinical Pregnancy Toxemia-Induced Gene Expression Changes in Ovine Placenta and Uterus
por: Kasimanickam, Ramanathan K.
Publicado: (2016)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Neurofilaments are obligate heteropolymers in vivo
Publicado: (1993)

Studies on the biosynthesis of neurofilament proteins
Publicado: (1980)

Neurofilament Transport Is Bidirectional In Vivo
por: Boyer, Nicholas P., et al.
Publicado: (2022)

Monitoring of radiologic disease activity by serum neurofilaments in MS
por: Uher, Tomas, et al.
Publicado: (2020)

Myosin Va binding to neurofilaments is essential for correct myosin Va distribution and transport and neurofilament density
por: Rao, Mala V., et al.
Publicado: (2002)

Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels
por: Kušnierová, Pavlína, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9f1rj88vsh3oq7sktqorfssoae